Patents by Inventor Michael Joseph Bishop

Michael Joseph Bishop has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230287028
    Abstract: Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).
    Type: Application
    Filed: April 28, 2023
    Publication date: September 14, 2023
    Inventors: Michael Joseph BISHOP, Eugene L. Stewart, Katherine Louisa Widdowson, James Walter Janetka, Laurel Kathryn McGrane
  • Patent number: 11697665
    Abstract: Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: July 11, 2023
    Assignees: Fimbrion Therapeutics, Inc., GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Michael Joseph Bishop, Eugene L. Stewart, Katherine Louisa Widdowson, James Walter Janetka, Laurel Kathryn McGrane
  • Publication number: 20220298197
    Abstract: Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in human subjects are also provided for the treatment diseases such as urinary tract infection.
    Type: Application
    Filed: May 6, 2020
    Publication date: September 22, 2022
    Inventors: Michael Joseph BISHOP, James Walter JANETKA, Laurel Kathryn MCGRANE, Eugene Lee STEWART, Katherine Louisa WIDDOWSON
  • Publication number: 20220242900
    Abstract: Disclosed herein are new O-biphenyl- and O-phenylheteroarylmannoside compounds and compositions and their application as pharmaceuticals for use in the treatment of human disease. Methods of inhibition of FimH activity in human subjects are also provided for the treatment of diseases such as urinary tract infection.
    Type: Application
    Filed: June 17, 2020
    Publication date: August 4, 2022
    Inventors: Michael Joseph BISHOP, James Walter JANETKA, Laurel Kathryn MCGRANE, Katherine Louisa WIDDOWSON
  • Publication number: 20210395287
    Abstract: Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).
    Type: Application
    Filed: July 9, 2021
    Publication date: December 23, 2021
    Inventors: Michael Joseph BISHOP, Eugene L. STEWART, Katherine Louisa WIDDOWSON, James Walter JANETKA, Laurel Kathryn MCGRANE
  • Patent number: 11111262
    Abstract: Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment diseases such as urinary tract infection.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: September 7, 2021
    Assignees: GlaxoSmithKline Intellectual Property Development Limited, Fimbrion Therapeutics, Inc.
    Inventors: Michael Joseph Bishop, Eugene L. Stewart, Katherine Louisa Widdowson, James Walter Janetka, Laurel Kathryn McGrane
  • Publication number: 20210017212
    Abstract: Disclosed herein are new C-mannoside compounds and compositions and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment diseases such as urinary tract infection.
    Type: Application
    Filed: October 6, 2020
    Publication date: January 21, 2021
    Inventors: Michael Joseph BISHOP, Vincent J. Colandrea, Yuehu Li, Eugene L. Stewart, Iulia Strambeanu, Katherine Louisa Widdowson, James Walter Janetka, Laurel Kathryn Mcgrane
  • Publication number: 20140323487
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 30, 2014
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Patent number: 8822518
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: September 2, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Publication number: 20140100255
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: December 12, 2013
    Publication date: April 10, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu ZHANG, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Patent number: 8633175
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Grant
    Filed: August 8, 2007
    Date of Patent: January 21, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Publication number: 20110124559
    Abstract: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.
    Type: Application
    Filed: August 8, 2007
    Publication date: May 26, 2011
    Applicant: Smithkline Beecham Corporation
    Inventors: David John Cowan, Andrew Lamont Larkin, Cunyu Zhang, David Lee Musso, Gary Martin Green, Rodolfo Cadilla, Paul Kenneth Spearing, Michael Joseph Bishop, Jason Daniel Speake
  • Patent number: 6884801
    Abstract: Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: April 26, 2005
    Assignee: SmithKline Beecham Corporation
    Inventors: Eric Cleveland Bigham, Michael Joseph Bishop, David Harold Drewry, Deanna Trojan Garrison, Stephen Joseph Hodson, Frank Navas, III, Jason D. Speake